ABSTRACT
INTRODUCTION
Alzheimer's disease (AD) is a neurodegenerative brain disorder and the first cause of dementia in elderly individuals. The cerebral extraneuronal lesions called senile plaques represent a defining histopathological characteristic of AD (Duyckaerts et al., 2009; SerranoPozo et al., 2011) . Senile plaques are formed by the deposition of amyloid-β (Aβ), a series of peptides produced by sequential endoproteolysis of the amyloid precursor protein (APP) by the action of two proteases, β-and γ-secretases (De Strooper et al., 2010; Haass and (Benilova et al., 2014; Maloney et al., 2014) . In this context, there is strong interest in identifying selective interventions aimed at preventing or lowering Aβ accumulation in the AD brain (Citron, 2010) .
The calcium homeostasis modulator protein 1 (CALHM1) gene (Dreses-Werringloer et al., 2008) was identified by using an expression profiling method (Aguilar et al., 2008) , which screened for genes that: (i) were preferentially expressed in the hippocampus-a brain region affected at the early stages of AD (de Leon et al., 2007)-and (ii) were located on susceptibility loci for AD. CALHM1 does not appear to be a risk gene for AD, but independent genetic studies have shown that it influences the onset of AD (DresesWerringloer et al., 2008; Lambert et al., 2010) . CALHM1 was proposed to control Aβ levels in cell cultures (Dreses-Werringloer et al., 2008; Vingtdeux et al., 2014) and in human cerebrospinal fluid (CSF) (Kauwe et al., 2010; Koppel et al., 2011) , but see also (Giedraitis et al., 2010) . Together, these data warrant further investigation aimed at determining whether CALHM1 is involved in molecular mechanisms relevant to AD pathogenesis (Berridge, 2010) .
CALHM1 is expressed in the human and mouse brains, and in hippocampal and cortical neurons (Dreses-Werringloer et al., 2008; Dreses-Werringloer et al., 2013; Ma et al., 2012) . CALHM1 function in brain neurons remains incompletely understood. Several studies have determined, however, that CALHM1 is a voltage-gated, pore-forming protein of a plasma membrane Ca 2+ -permeable channel regulated by extracellular Ca 2+ concentration (Dreses-Werringloer et al., 2008; Ma et al., 2012; Tanis et al., 2013) . Its expression and activation in different cell systems induce Ca 2+ influx and elevate cytoplasmic Ca 2+ concentration in response to a drop in extracellular Ca 2+ concentration (Dreses-Werringloer et al., 2008; Dreses-Werringloer et al., 2013) . In mouse cortical neurons, CALHM1 responds to extracellular Ca 2+ not only by elevating intraneuronal Ca 2+ levels, but also by controlling cell excitability (Ma et al., 2012 In the present study, we show that CALHM1 controls Aβ metabolism, in cell cultures and in vivo in the mouse brain, by facilitating a neuronal and Ca 2+ -dependent mechanism of extracellular clearance of Aβ. Aβ steady-state levels in the brain are known to be the result of a balance between its production from APP and its degradation by efficient clearance mechanisms. Aβ clearance is controlled by various pathways, which include endocytosis by several brain cell types (including glia and neurons), transport/binding mechanisms across the blood brain barrier, and extracellular enzymatic degradation (Pflanzner et al., 2010;  Journal of Cell Science Accepted manuscript Zolezzi et al., 2014) . In the enzymatic pathway, Aβ can be degraded in vivo by at least four peptidases from the metallopeptidase family: Neprilysin (NEP), endothelin-converting enzyme-1 and -2 (ECE-1 and -2), and insulin-degrading enzyme (IDE) (Turner and Nalivaeva, 2007) . Here, we also report that CALHM1 activation lowered extracellular Aβ levels by promoting Aβ clearance by IDE via a mechanism facilitating IDE secretion. This work reveals a previously unrecognized function of CALHM1 in neurons and identifies CALHM1 ion channel as an endogenous regulator of Aβ degradation in the brain. (Ma et al., 2012) . Concordant studies have demonstrated that normal electrical activity in neurons can result in a robust drop of [Ca 2+ ]o (up to concentrations < 0.1 mM) in the interstitium and synaptic clefts of the brain (Rusakov and Fine, 2003) . Thus, neuronal activity reduces [Ca 2+ ]o within the range of CALHM1 activation (Ma et al., 2012 (Ma et al., 2012) , respectively. Figure 1F shows that, compared to WT CALHM1, the three functionally defective CALHM1 mutants, N140A, W114A, and D121R, all failed to reduce Aβ levels. The lack of effect of these 3 mutants on Aβ accumulation could not be explained by defects in CALHM1 protein expression or stability (Fig. 1F ).
RESULTS

CALHM1 ion channel and extracellular
We then determined whether extracellular Ca 2+ is required for the effect of CALHM1 on Aβ levels. As expected, CALHM1-mediated Ca 2+ influx in 0.2 mM Ca 2+ aCSF could be inhibited by the chelating agent EGTA (2 mM, see Fig. 1G ). In these conditions, the effect of CALHM1 activation on Aβ levels was also noticeably blocked ( 
CALHM1 promotes extracellular Aβ degradation by a soluble proteolytic activity
The effect of CALHM1 on Aβ levels could be due to a decrease in Aβ production from APP or to an increase in intracellular or extracellular Aβ degradation (Leissring and Turner, 2013) .
We observed no reduction in intracellular Aβ levels upon conditions of CALHM1 expression
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and activation in 0.2 mM Ca 2+ aCSF ( Fig. 2A) . Moreover, treatment with the lysosomotropic drugs NH4Cl and chloroquine, which neutralize Aβ lysosomal degradation (Nixon et al., 2008; Vingtdeux et al., 2010) , did not prevent the decrease of extracellular Aβ by CALHM1
( Fig. 2A ).
We next assessed the effect of CALHM1 on the rate of Aβ production. To this end, to progressively restore APP processing and Aβ production ( Fig. 2B ). We found no effect of CALHM1 expression and its activation on the rate of restoration of Aβ production, whereas, as expected, extracellular Aβ accumulation was strongly inhibited by CALHM1 activation (Fig. 2C ). Thus, CALHM1 had no effect on either Aβ production or intracellular Aβ degradation by the lysosomes.
We then investigated whether CALHM1 promotes extracellular Aβ degradation and whether a membrane-associated or soluble proteolytic activity is involved in this mechanism.
In a cell-free assay, we incubated at 37 o C the conditioned medium (CM) of CALHM1-transfected cells (which were activated in 0.2 mM Ca 2+ aCSF) with exogenous Aβ from the CM of APP-transfected cells (see Fig. 2D ). In these conditions, we observed a robust degradation of exogenous Aβ by the CM of cells expressing activated CALHM1, whereas the CM of non-transfected cells or cells transfected with a control vector had no effect on Aβ levels ( Fig. 2E ). These data show that upon CALHM1 activation, Aβ is targeted for degradation in the extracellular space by a soluble proteolytic activity.
CALHM1 promotes extracellular Aβ degradation by IDE
Extracellular Aβ proteolytic clearance is mediated in vivo by at least four peptidases from the metallopeptidase family: NEP, ECE-1 and -2, and IDE (Turner and Nalivaeva, 2007 Together these results show that CALHM1 ion channel promotes extracellular Aβ degradation by IDE via an increase in IDE secretion.
CALHM1 deficiency decreases IDE activity in the mouse brain
To determine whether CALHM1 controls cerebral IDE activity, we first assessed the in vitro degradation of exogenous Aβ and insulin by Calhm1 KO and WT brain homogenates.
Calhm1 KO mice were recently generated in our laboratory and are viable and fertile (Dreses-Werringloer et al., 2013; Ma et al., 2012; Taruno et al., 2013) . Histological analyses have revealed that Calhm1 KO mice display no defects in brain development or brain integrity in adulthood (unpublished observations), which make them a relevant model to study CALHM1 functions in the brain.
IDE is secreted but can also be found as a membrane-bound enzyme outside the cell (Vekrellis et al., 2000) . Soluble and membrane-associated brain homogenates were prepared from adult WT (Calhm1 +/+ ) and Calhm1 KO (Calhm1 -/-) mice, and were analyzed for synthetic Aβ and recombinant insulin degradation in an in vitro assay (see Methods).
Strikingly, both soluble and membrane-associated brain homogenates contained significantly lower levels of Aβ degradation activity in CALHM1-deficient mice, compared to WT mice (Figs. 4A and B) . Aβ degradation activity measured in this in vitro assay in the membraneassociated brain homogenates was almost entirely sensitive to insulin and PNT (Fig. 4C) ,
indicating that the proteolytic activity directed against Aβ measured in this assay is mostly due to IDE. Insulin degradation activity in these homogenates was significantly inhibited by PNT, confirming that IDE is also the main proteolytic activity directed against insulin in our assay (Fig. 4D ). In line with the results obtained for synthetic Aβ degradation, Calhm1 KO
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brain homogenates showed a clear trend of reduction in insulin degradation activity, compared to WT brain homogenates (Fig. 4E ).
APP intracellular domain (AICD) is the C-terminal fragment of APP produced by γ-secretase (Marambaud and Robakis, 2005) . Previous studies have found that IDE targets AICD for degradation in cell cultures (Edbauer et al., 2002) and in vivo in mice (Farris et al., 2003; Miller et al., 2003) . IDE subcellular localization is unconventional and the exact trafficking pathways leading to its presence both outside the cell and in the cytosol remain to be clearly defined. Using subcellular fractionation, we confirmed that intracellular IDE was mainly found as a soluble pool in the cytosol (Fig. 5A ). This localization of IDE in the cytosol is consistent with its role in AICD degradation (Edbauer et al., 2002; Vekrellis et al., 2000) .
AICD metabolism (production and degradation), like the metabolism of other protein fragments produced by γ-secretase, can be followed in vitro by incubating at 37 o C membranes isolated from cell or brain tissue homogenates (Marambaud et al., 2003) . Using this membrane assay, we preincubated brain homogenates in vitro for 2 hours to produce the γ-secretase inhibitor-sensitive AICD fragment (Fig. 5B) . AICD degradation was then assessed by incubating the homogenates for 5 hours (Fig. 5B, 0 to 5 hours). In these conditions, a decrease of AICD levels was readily detectable and the rate of AICD degradation could be quantified (Figs. 5B and C) . Importantly, the decrease over time of AICD levels was fully protected by PNT treatment (Fig. 5B) , confirming the implication of IDE in AICD degradation in this assay. Because no increase in AICD levels were observed over time in the presence of PNT, we concluded that AICD production after the 2 hours preincubation reached saturation levels (Fig. 5B) . Under these conditions, we found a significant decrease in AICD degradation activity in Calhm1 KO brain membranes, compared to membranes isolated from WT brains (Figs. 5B and C) . Together, these data show that CALHM1 deficiency decreases brain IDE activity.
CALHM1 deficiency increases endogenous Aβ and AICD levels in the mouse brain
Αβ in the brain is mainly produced by neurons. IDE, however, is ubiquitously expressed and could potentially control extracellular Αβ levels by being released from other cell types than neurons. Because CALHM1 is expressed in cerebral neurons (Dreses-Werringloer et al., 2013; Ma et al., 2012) , we asked whether CALHM1 deficiency affects the steady-state levels of endogenously produced Aβ in isolated whole forebrain primary neuron cultures. We found that Calhm1 KO neurons accumulated significantly more Aβ42 over time than neurons isolated from WT mice (Fig. 6A) . The effect of CALHM1 deficiency on Aβ42 accumulation was abolished by the IDE competitive inhibitor insulin (Fig. 6B) 
DISCUSSION
In the current study, we show that CALHM1 is a repressor of Aβ accumulation in cell lines and in vivo in the mouse brain. We determined that CALHM1 acted by promoting an extracellular mechanism of Aβ degradation. Using pharmacological and RNAi approaches, we identified IDE as the protease solely responsible for CALHM1-dependent Aβ degradation. These results were corroborated by the analyze of the Calhm1 KO mice that displayed a consistent decrease in cerebral IDE activity, which was accompanied by a significant elevation of endogenous Aβ levels, in both the whole brain and primary neurons.
Additional investigation in cell cultures revealed that CALHM1 promoted IDE-mediated Aβ degradation by triggering IDE secretion.
The importance of these results is two-fold. A main therapeutic strategy for drug development in AD is focusing on approaches aimed at interfering with Aβ accumulation in the brain (Citron, 2010) . Furthermore, ion channels, and more specifically cell-surface ion channels that are more easily accessible, are targets of choice for drug development (Clare, 2010) . In this context, our data not only reveal new insights into CALHM1 biology and its relevance to AD pathogenesis, but also warrant further investigation aimed at determining whether anti-amyloidogenic CALHM1 activating interventions can be identified.
The localization and substrate accessibility of IDE is complex and its exact trafficking is only partially understood (Leissring and Turner, 2013) . IDE can be found in the cytosol, where it degrades AICD, or outside the cell to regulate the catabolism of several soluble peptides (Turner and Nalivaeva, 2007) . At the mechanistic level, our study identified a role for CALHM1 in IDE cellular secretion. By using a cell membrane fractionation method, we found a reduction in the activity of not only soluble IDE but also membrane-associated IDE in the brain. Our data therefore suggest that CALHM1 could also be involved in other mechanisms of IDE activation or substrate accessibility not only extracellularly but also in the cytosol, as suggested by the observed effect of CALHM1 on AICD levels. Further studies will
Journal of Cell Science Accepted manuscript be needed to address this possibility and determine which mechanisms of IDE maturation or trafficking might also be modulated by CALHM1. (Ma et al., 2012; Siebert et al., 2013; Taruno et al., 2013) . CALHM1 permeability activation is therefore expected to result in the control of multiple signaling pathways that could potentially also contribute to different mechanisms of IDE activation and to the observed effect on Aβ clearance. In this context, additional studies will have to determine whether Ca 2+ influx through CALHM1 is the only trigger for Aβ clearance or whether other pathways controlled by CALHM1 permeability for different ions or molecules are also required.
In summary, this work shows for the first time that CALHM1 is an ion channel that has anti-amyloidogenic properties in vivo in the mammalian brain. Specifically, we found that CALHM1 promoted a neuronal and Ca 2+ -dependent mechanism of extracellular Aβ degradation by IDE. These data warrant further investigation aimed at determining whether CALHM1 ion channel activity can be pharmacologically targeted for promoting amyloid clearance in the AD brain.
MATERIALS AND METHODS
Chemicals, plasmids, and antibodies
Ruthenium Red, ZnCl2, NH4Cl, chloroquine, 1,10-phenanthroline, and insulin were purchased from Sigma-Aldrich. Phosphoramidon was from Cayman Chemical and thiorphan from Enzo Life Sciences. BFA was from Epicentre Technologies. Plasmids containing Mycor V5-tagged WT and mutant (N140A and W114A) human and mouse CALHM1 cDNAs were described previously (Dreses-Werringloer et al., 2008; Dreses-Werringloer et al., 2013) . V5-tagged D121R-CALHM1 mutant was created using QuickChange II site-directed mutagenesis kit (Agilent technologies) and confirmed by sequencing. Anti-Aβ1-17 (6E10) and anti-Aβ17-24 (4G8) antibodies were from Covance, and anti-APP1-200 antibody (LN27)
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from Zymed Laboratories Inc. Anti-APP C-terminal domain antibody (R1) was described before (Vingtdeux et al., 2010) . Anti-IDE and anti-TSG101 antibodies were from Abcam, anti-Myc and anti-MEK1/2 from Cell Signaling Technology, anti-V5 antibody from Invitrogen, anti-actin antibody from BD Transduction Laboratories, and anti-transferrin receptor antibody from Invitrogen.
Mice
All animal experiments were performed according to procedures approved by the Feinstein Institute for Medical Research Institutional Animal Care and Use Committee. The Calhm1 KO mice were described elsewhere (Dreses-Werringloer et al., 2013; Taruno et al., 2013) .
Cell cultures, transfections, and drug treatments
Naïve N2a 
Western blot (WB) and immunoprecipitation (IP) analyses
Cells were washed with phosphate-buffered saline (PBS) and solubilized in RIPA buffer (Millipore) supplemented with 1x Complete protease inhibitor mixture (Roche Applied Science). Depending on the primary antibody used, 5-20 μg of cell extracts were analyzed by SDS-PAGE. Conditioned medium containing secreted total Aβ, sAPPα, and IDE was analyzed by direct WB, as described before (Vingtdeux et al., 2010) . Intracellular Aβ levels
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were analyzed in cells harvested by trypsinization and by IP using 4G8 antibody, as described before (Vingtdeux et al., 2010) .
Brain IDE in vitro degradation assays
Brains from 6-month-old Calhm1 +/+ and Calhm1 -/-mice were homogenized in 8 volumes (wt/v) of 250 mM sucrose in 50 mM Tris-HCl, pH 7.4. Nuclei were pelleted and the supernatants were centrifuged at 100,000 x g for 1 h. Resulting supernatants were saved as soluble fractions and membrane pellets were resuspended in 100 mM Na2CO3, pH 11.3 and centrifuged at 100,000 x g for 1 h. Pellets were resuspended in 50 mM Tris-HCl, pH 7.4 and sonicated. Protein concentration in soluble and membrane fractions were evaluated using BCA assay. To quantify proteolysis of Aβ by brain fractions, 100 pM of synthetic human Aβ1-42 (Invitrogen) was incubated at 37°C with 100 µg/mL proteins of soluble or membrane fractions. At each time points, an aliquot of the sample was removed and stored at -80°C until analysis. To measure proteolysis of insulin, 100 pM of recombinant human insulin (Sigma) was incubated at 37°C with 50 µg/mL proteins of the membrane fraction. ELISA was used to determine Aβ (Wako) and insulin (ALPCO Diagnostics) concentrations.
Subcellular fractionation
N2a cells were homogenized in Buffer A (10 mM NaCl, 1.5 mM MgCl2, 2 mM DTT, 10 mM Tris-HCl, pH 7.4) using 50 strokes of the pestle of a tight-fitting Dounce. Buffer B (525 mM mannitol, 175 mM sucrose, 2.5 mM EDTA, 12.5 mM Tris-HCl, pH 7.4) was then added at a 4:10 ratio to the cell homogenate in Buffer A. The resulting homogenate was centrifuged at 1,300 x g for 10 min to remove the nuclei. Supernatant was centrifuged at 20,000 x g for 45 min to isolate a first fraction (20K, enriched in the cell surface marker transferrin receptor).
Supernatant was then centrifuged at 100,000 x g for 3 h to isolate a second fraction (100K, enriched in both transferrin receptor and the ESCRT-I subunit TSG101). The final supernatant contained the soluble cytosolic proteins and was enriched in the cytosolic marker MEK1/2. Intact vesicles from the 100K fraction were trypsinized (0.25% trypsin for 10 min at 37 o C) to degrade proteins exposed to the cytosol.
In vitro AICD degradation assay
Cell membranes were obtained from brains of 6-month-old Calhm1 +/+ and Calhm1 -/-mice using the in vitro γ-secretase assay described before (Marambaud et al., 2003) . AICD was generated by incubation of the membrane preparations at 37°C for 2 h in a volume of 25 µL/assay. Samples were further incubated for 5 hours to monitor AICD degradation. AICD levels were then analyzed by WB using R1 antibody. Journal of Cell Science Accepted manuscript Journal of Cell Science Accepted manuscript 
Journal of Cell Science Accepted manuscript
